188 related articles for article (PubMed ID: 2418898)
1. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production.
Dover GJ; Humphries RK; Moore JG; Ley TJ; Young NS; Charache S; Nienhuis AW
Blood; 1986 Mar; 67(3):735-8. PubMed ID: 2418898
[TBL] [Abstract][Full Text] [Related]
2. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea.
Veith R; Galanello R; Papayannopoulou T; Stamatoyannopoulos G
N Engl J Med; 1985 Dec; 313(25):1571-5. PubMed ID: 2415821
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
Rodgers GP
Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
[TBL] [Abstract][Full Text] [Related]
5. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis.
Letvin NL; Linch DC; Beardsley GP; McIntyre KW; Miller BA; Nathan DG
J Clin Invest; 1985 Jun; 75(6):1999-2005. PubMed ID: 2409112
[TBL] [Abstract][Full Text] [Related]
6. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
Koshy M; Dorn L; Bressler L; Molokie R; Lavelle D; Talischy N; Hoffman R; van Overveld W; DeSimone J
Blood; 2000 Oct; 96(7):2379-84. PubMed ID: 11001887
[TBL] [Abstract][Full Text] [Related]
7. Increasing fetal hemoglobin production in sickle cell disease: results of clinical trials.
Dover GJ; Charache S
Prog Clin Biol Res; 1987; 251():455-66. PubMed ID: 2448813
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
9. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens.
Dover GJ; Charache S; Boyer SH; Vogelsang G; Moyer M
Blood; 1985 Sep; 66(3):527-32. PubMed ID: 2411310
[TBL] [Abstract][Full Text] [Related]
10. Influence of hydroxyurea on fetal hemoglobin production in vitro.
Miller BA; Platt O; Hope S; Dover G; Nathan DG
Blood; 1987 Dec; 70(6):1824-9. PubMed ID: 2445401
[TBL] [Abstract][Full Text] [Related]
11. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ
Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341
[TBL] [Abstract][Full Text] [Related]
12. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
Maier-Redelsperger M; de Montalembert M; Flahault A; Neonato MG; Ducrocq R; Masson MP; Girot R; Elion J
Blood; 1998 Jun; 91(12):4472-9. PubMed ID: 9616141
[TBL] [Abstract][Full Text] [Related]
13. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin.
Humphries RK; Dover G; Young NS; Moore JG; Charache S; Ley T; Nienhuis AW
J Clin Invest; 1985 Feb; 75(2):547-57. PubMed ID: 2579100
[TBL] [Abstract][Full Text] [Related]
14. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
Dover GJ; Charache S; Boyer SH
Trans Assoc Am Physicians; 1984; 97():140-5. PubMed ID: 6085527
[No Abstract] [Full Text] [Related]
15. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
16. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Fucharoen S; Siritanaratkul N; Winichagoon P; Chowthaworn J; Siriboon W; Muangsup W; Chaicharoen S; Poolsup N; Chindavijak B; Pootrakul P; Piankijagum A; Schechter AN; Rodgers GP
Blood; 1996 Feb; 87(3):887-92. PubMed ID: 8562958
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia.
Charache S; Dover GJ; Moyer MA; Moore JW
Blood; 1987 Jan; 69(1):109-16. PubMed ID: 2431728
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F
Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic manipulation of fetal hemoglobin synthesis.
Dover GJ; Humphries RK; Young N; Ley T; Boyer S; Charache S; Nienhuis A
Prog Clin Biol Res; 1985; 191():447-54. PubMed ID: 2413480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
